Saltar al contenido
Merck

SML1026

Sigma-Aldrich

Lasofoxifene tartrate

≥98% (HPLC)

Sinónimos:

(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate, (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate, CP-336,156 tartrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C28H31NO2 · C4H6O6
Número de CAS:
Peso molecular:
563.64
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

SMILES string

OC1=CC=C(C(CC[C@@H]2C3=CC=CC=C3)=C1)[C@H]2C4=CC=C(OCCN5CCCC5)C=C4.O=C(O)[C@@H](O)[C@H](O)C(O)=O

InChI

1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

InChI key

INEHJXCWEVNEDZ-LUDNRVPPSA-N

Biochem/physiol Actions

Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
Lasofoxifene possesses strong resistance to intestinal wall glucuronidation and thus promotes oral bioavailability. In postmenopausal women, it reduces bone resorption, bone loss and low density lipoprotein (LDL) cholesterol. Selective and regular dose of Lasofoxifene is known to reduce the risk of fractures, breast cancer, major coronary heart disease, and stroke.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Lasofoxifene in postmenopausal women with osteoporosis.
Cummings S R, et al.
The New England Journal of Medicine, 362(8), 686-696 (2010)
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Gennari L, et al.
Expert Opinion on Investigational Drugs, 15(9), 1091-1103 (2006)
Nam Sook Kim et al.
Journal of separation science, 43(14), 2750-2765 (2020-04-17)
An analytical method for the simultaneous and reliable determination of 20 antigout and antiosteoporosis pharmaceutical compounds in adulterated health food products was developed using liquid chromatography with electrospray ionization tandem mass spectrometry and liquid chromatography with quadrupole-time-of-flight mass spectrometry. The
Nam Sook Kim et al.
Journal of pharmaceutical and biomedical analysis, 179, 113003-113003 (2019-12-10)
The aim of this study was to simultaneously determine the presence of unauthorized drug substances in health foods and herbal products used in the treatment of conditions such as gout and anti-osteoporosis. Therefore, we developed and optimised a rapid and
Kaitlyn J Andreano et al.
Breast cancer research and treatment, 180(3), 635-646 (2020-03-05)
The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular injections to

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico